500+ person global organization spans 25+ countries with operations across North America, Europe, Africa, Latin America, and Asia-Pacific

LEUVEN, Belgium, and ZEIST, Netherlands – Nov. 19, 2025 – P95 and Julius Clinical today announced that they have merged to form a leading global, full-service clinical research organization (CRO) with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. The combined organization includes more than 500 professionals in over 25 countries and delivers clinical development and real-world evidence (RWE) programs across five continents.

This merger brings together the complementary strengths of both companies, Julius Clinical’s global clinical trial expertise and P95’s leadership in epidemiology, infectious diseases, vaccines, and RWE, creating a unified, science-led platform that supports biopharmaceutical and public health partners across the entire development lifecycle. Over the past five years, the organizations have delivered hundreds of neuroscience, cardio-renal-metabolic, and infectious disease programs, including large global clinical trials, epidemiology studies, and global RWE projects.

The combined company will be led by Bassem Saleh, M.D., CEO of Julius Clinical, who will serve as Chief Executive Officer. Thomas Verstraeten, M.D., founder and CEO of P95, will work alongside Dr. Saleh during the integration and will continue to support the organization as a Board Member and Senior Advisor, ensuring continuity of scientific leadership and strategic direction.

“P95 and Julius Clinical share a deep scientific foundation and a mission to improve global health,” said Dr. Saleh. “As the CEO of the combined organizations, I am fully committed to the exceptional teams, cultures, and partners that have driven both companies’ success. I am honored to carry these two organizations forward together as we continue to deliver unmatched high-quality, science-led research across the full development lifecycle, supporting innovation that improves lives worldwide.”

“I could not be prouder of what the P95 team has achieved over the past decade, building a company recognized for its scientific integrity, commitment to public health, and meaningful partnerships around the world,” said Dr. Verstraeten. “This merger with Julius Clinical represents an exciting next chapter. By combining our strengths, we gain the reach and scalability that our clients and public health partners increasingly need to advance research that truly makes a global impact.”

The combined company is supported by Ampersand Capital Partners, a long-standing investor in both organizations. Ampersand will continue to partner closely with the company as it expands its global footprint, strengthens its capabilities, and accelerates its growth strategy.

With staff across North America, Europe, Africa, Latin America, and Asia-Pacific, the company provides global reach with deep local expertise. Its team spans clinical operations, epidemiology, biostatistics, data science, medical leadership, and scientific consulting, enabling flexible full-service, functional-service, and single-service models. Clients, including large and mid-sized pharmaceutical companies, biotech innovators, and leading public health institutions, will benefit from the expanded scale, scientific depth, and integrated clinical and RWE strategy.

About AKEURA

AKEURA is a specialist contract research organization (CRO) with dual expertise in clinical and real-world settings, from early- through late-phase clinical development to real-world evidence (RWE). With more than 25 years of experience and more than 500 researchers, clinicians, and scientists across five continents, AKEURA helps sponsors advance medicines across their full lifecycle, with an exclusive focus on three therapeutic areas: neuroscience, infectious diseases and vaccines, and cardiometabolic diseases. In each, it brings the experience, reach, and hands-on expertise to give every promising medicine the study it deserves. Formerly P95 Julius Clinical, AKEURA is headquartered in Zeist, the Netherlands, and backed by Ampersand Capital Partners. Learn more at akeura.com.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $4 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With hubs in Boston, Amsterdam, and London, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn.